Nivolumab Plus Chemotherapy versus Placebo Plus Chemotherapy in Korean Patients with HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer: Subgroup Analysis of a Randomized, Multicenter, Double-Blind Phase 3 Trial (ATTRACTION-4).

Cancer Res Treat · 2026 · PMC13382558 · PMID 40610007

Europe PMC DOI

hedged sentence

0.0650

closest p · 1.3× alpha

0.0650

boldest claim

The sentences

did not reach statistical significancep=0.065so close (0.05 < p ≤ 0.1)

4A , median OS was numerically longer in the nivolumab+chemotherapy group than in the placebo+chemotherapy group, although this did not reach statistical significance (19.71 vs. 14.88 months; HR, 0.78; 95% CI, 0.60 to 1.02; p=0.065) ( Fig. 4A ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.